Arvinas (ARVN)
Develops PROTAC degraders around VEPPANU and clinical oncology, neurology, and neuromuscular programs.
Something off on this page? Send us feedback.
Builds targeted protein degradation therapies from a New Haven PROTAC platform. VEPPANU is approved in the U.S. and licensed globally to Rigel, while the remaining pipeline is centered on investigational oncology, neurology, and neuromuscular degrader programs.
Builds targeted protein degradation medicines from a New Haven PROTAC platform with Yale-linked origins. The current portfolio centers on VEPPANU, an FDA-approved oral PROTAC estrogen receptor degrader, plus clinical programs including ARV-102, ARV-027, ARV-806, and ARV-393.
Commercial exposure is partner-led rather than a standard product-sales model. Rigel holds exclusive global development, manufacturing, and commercialization rights to VEPPANU, while Arvinas and Pfizer remain tied to ongoing development activities and license economics.
The pipeline spans oncology, neurology, and neuromuscular disease, and reporting remains a single consolidated segment. The business depends on partnered execution for VEPPANU and on clinical progress across investigational degrader programs.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 10, 2026 | Morgan Stanley | Target | Target: $12 | Target: $10 |
| Aug 10, 2026 | Evercore ISI | Target | Target: — | Target: $14 |
| Aug 5, 2026 | Wedbush | Reiterate | Rating: —Target: $11 | Target: $12 |
| Aug 5, 2026 | Wells Fargo | Downgrade | ||
| Aug 4, 2026 | Wells Fargo | Target | Target: $26 | Target: $11 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $567.9M · Total debt $8.2M · Total assets $675.1M · Shareholders' equity $562.2M
- Revenue
- $249.7M
- Operating income
- $164.1M
- Net income
- $169.4M
No dividends on record.
| Institutions | 85.82% | 56.12M shares | |
|---|---|---|---|
| 206 holders · as of Jun 30, 2026 | |||
| Insiders | 2.19% | 1.43M shares | |
| 14 holders · as of Jun 26, 2026 | |||
| Other | 11.99% | 7.84M shares | |
| remainder | |||
65.39M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 11.64% | 7.61M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 6.31% | 4.12M | as of Jun 30, 2026 |
D. E. Shaw & Co., Inc.Institution | 5.35% | 3.50M | as of Jun 30, 2026 |
Pfizer IncInstitution | 5.29% | 3.46M | as of Jun 30, 2026 |
D. E. Shaw & Co., L.P.Institution | 5.21% | 3.41M | filed Nov 14, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 24, 2026 | Andrew Saik | officer: Chief Financial Officer | −5,696 | $8.16 |
| Jun 17, 2026 | Angela M. Cacace | officer: Chief Scientific Officer | −2,576 | $7.60 |
| May 21, 2026 | Randy Teel | director, officer: President and CEO | −2,209 | $9.04 |
| May 11, 2026 | Randy Teel | director, officer: President and CEO | −9,657 | $9.94 |
| May 11, 2026 | Noah Berkowitz | officer: Chief Medical Officer | −11,108 | $9.94 |
- Kymera Therapeutics
Oral TPD peer in immunology and partnered oncology
- Nurix Therapeutics
Clinical TPD peer in BTK and oncology degraders
- AstraZeneca (ADR)
Large pharma rival in ER degrader breast-cancer therapy
- C4 Therapeutics
Oncology degrader platform peer across MM, NHL, and solid tumors
- Novartis (ADR)
Breast-cancer pharma rival and TPD licensing participant
- Monte Rosa Therapeutics
Molecular-glue degrader peer in oncology and immunology
- Foghorn Therapeutics
Chromatin and degrader oncology peer with ER+ breast work
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Arvinas | $8.44 | +1.73% | $535.5M | 51.9 | — | 1.7 | +1,014.7% |
| Kymera Therapeutics | $120.79 | +2.65% | $9.68B | — | — | 92.2 | +466.4% |
| Nurix Therapeutics | $25.66 | +0.99% | $2.64B | — | — | 71.7 | −79.5% |
| AstraZeneca (ADR) | $168.47 | +0.22% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| C4 Therapeutics | $3.34 | +1.36% | $364.9M | — | — | 10.4 | +2.8% |
| Novartis (ADR) | $141.18 | +0.14% | $267.96B | 21.3 | 15.0 | 4.8 | +0.9% |
| Monte Rosa Therapeutics | $12.31 | +0.38% | $1.04B | — | — | 36.1 | −61.2% |
| Foghorn Therapeutics | $4.25 | +2.31% | $243.7M | — | — | 6.6 | +113.1% |
| Median | 23.3 | 15.4 | 10.4 | +2.8% |